WHO AWaRe Classification of Antibiotics

A patient is admitted with an uncomplicated urinary tract infection, the kind that a narrow-spectrum oral antibiotic would clear. Instead, the ward reaches for a broad-spectrum carbapenem, "to be safe."

The infection resolves, but something invisible has happened: a last-line drug has been spent on an infection that never needed it, nudging the ward's bacteria one step closer to carbapenem resistance. Multiply that choice across thousands of prescriptions and you have the engine of antimicrobial resistance.

The WHO AWaRe classification exists to make that choice visible: it sorts antibiotics not by how strong they are, but by how much their overuse threatens the future, so that the right drug is used for the right infection and the last-line drugs are protected.

What AWaRe is and why it exists

The AWaRe classification (Access, Watch, Reserve) is a tool the World Health Organization developed in 2017 to support antibiotic stewardship at local, national, and global levels and to slow antimicrobial resistance. It sorts antibiotics into three groups based on their impact on resistance and the need to monitor their use, and it is updated every two years alongside the WHO Model List of Essential Medicines. As of the most recent updates, WHO has classified more than 250 antibiotics into the three groups (the exact number rises with each two-year revision).

The purpose is not academic labeling. AWaRe is designed to be used: to monitor how much of each group a country or hospital consumes, to set stewardship targets, to guide which antibiotic is chosen for which infection, and to build local antibiotic policy. That applied purpose is the key to the whole framework.

Why a drug lands in each group

This is the single most important idea, and the one most students miss. A drug's AWaRe group is decided by its impact on antimicrobial resistance and the need to monitor its use, not by how clinically powerful it is. Two drugs can be equally effective for an infection and sit in different groups, because one drives resistance harder than the other.

With that principle, the three groups follow naturally:

Access

Access antibiotics are generally narrow-spectrum, active against common bacteria, with a lower potential to drive resistance and a well-established safety profile. They are the first- or second-choice empiric options for common infections and should be available everywhere. Examples: amoxicillin, amoxicillin-clavulanate, cefalexin, gentamicin, doxycycline, nitrofurantoin, metronidazole.

Watch

Watch antibiotics have higher resistance potential and include most of the critically important classes, cephalosporins, fluoroquinolones, carbapenems, macrolides. They are recommended for a narrower set of specific infections and are the key targets of stewardship monitoring, because overusing them selects for resistance quickly. Examples: ceftriaxone, cefixime, ciprofloxacin, azithromycin, meropenem, vancomycin.

Reserve

Reserve antibiotics are last-resort drugs, kept for confirmed or suspected infections caused by multidrug-resistant organisms when other options have failed. Their use should be tightly restricted and reported, to preserve them. Examples: colistin, linezolid, ceftazidime-avibactam, tigecycline, polymyxin B, plazomicin.

The gradient across the three is a gradient of resistance risk and the need to protect the drug, not a gradient of strength.

The three groups at a glance

Short representative tables follow; the full, current classification of every antibiotic is maintained by WHO and updated every two years. Check WHO AWaRe classification for the complete list.

Access group (representative examples)

Watch group (representative examples)

Reserve group (representative examples)

Access is not the weakest group

A natural assumption is that the groups run weak to strong: Access weak, Watch stronger, Reserve strongest. This is wrong, and WHO states so explicitly. Access antibiotics are not weaker; for many common infections they are the most effective drugs available. The groups reflect impact on resistance and need for surveillance, not clinical potency.

Two consequences worth holding onto. First, choosing an Access drug when it fits the infection is good medicine, not a compromise. Second, reaching for a Watch or Reserve drug "to be safe" is usually the opposite of safe: it is no more effective for a susceptible infection and it accelerates resistance. The whole point of AWaRe is to break the reflex that broader equals better.

The Access target: a stewardship yardstick

AWaRe is not just a label, it sets a measurable national goal. The original WHO target (2019-2023) was that at least 60% of a country's total antibiotic consumption should come from the Access group. In 2024, this was strengthened: all United Nations Member States committed to a target that, by 2030, 70% of human antibiotic use should be Access-group antibiotics.

The logic of the target: a country whose consumption is dominated by Access drugs is treating common infections with appropriate, lower-resistance-risk antibiotics. A country leaning heavily on Watch and Reserve drugs is either over-treating or facing high resistance, and is burning through its future options. The Access percentage is therefore a simple, powerful indicator of how healthy a country's antibiotic use is. (Note the specific figure, 60% then 70% by 2030, since much older material still cites only 60%.)

How AWaRe is applied in stewardship

AwaRe classification directly maps to what stewardship programs require.

Monitoring consumption. Hospitals and countries categorize their antibiotic use by AWaRe group to see where they stand against the Access target. A rising Watch or Reserve share flags a stewardship problem to investigate.

Setting formularies and antibiotic policy. Labs and hospitals use AWaRe to shape their formularies, making Access drugs the default first choice and placing restrictions (such as requiring approval or an infectious-diseases consult) on Watch and especially Reserve drugs.

Guiding empirical therapy. WHO publishes the AWaRe antibiotic book, which recommends specific first- and second-choice antibiotics, with dose and duration, for common infections in primary care and hospitals. It turns the classification into concrete prescribing guidance, favoring Access drugs for the infections where they work.

Protecting last-line drugs. Reserve-group use is tracked and reported so that these last-resort antibiotics are preserved for the multidrug-resistant infections that genuinely need them, an effort tied to the WHO priority pathogens that most threaten current treatment.

Used together, these turn AWaRe from a list into a working stewardship system: measure the mix, set the policy, guide the prescription, protect the last resort.

How to Remember

AWaRe sorts by resistance risk, not by strength. The one idea that unlocks everything. A drug's group reflects how much its use threatens future effectiveness, not how powerful it is. Amoxicillin (Access) is not weaker than meropenem (Watch); it is lower-risk for resistance.

Access, Watch, Reserve: use freely, use carefully, use last. The three groups as three prescribing attitudes. Access, the everyday first choice. Watch, higher resistance risk, use for specific indications and monitor. Reserve, last resort for multidrug-resistant infections, protect at all costs.

The critically important classes live in Watch. Cephalosporins, fluoroquinolones, carbapenems, macrolides, the broad-spectrum workhorses, are mostly Watch, precisely because they drive resistance. If a drug is broad-spectrum and heavily used, suspect Watch.

Aim for the Access majority: 70 by 2030. The stewardship target in four words. At least 70% of human antibiotic use should be Access by 2030 (up from the earlier 60%). A high Access share means healthy prescribing.

Key exam facts

Where Students Get Confused

AWaRe groups are not a strength ranking. The classification reflects a drug's impact on resistance and the need to monitor it, not how powerful it is. Access drugs are often the most effective choice for a given infection.

"Broader is safer" is the mistake AWaRe targets. Using a Watch or Reserve drug for a susceptible common infection is not safer; it is no more effective and it accelerates resistance. The right Access drug is the safe choice.

Where the critically important classes sit. Fluoroquinolones, third-generation cephalosporins, carbapenems, and macrolides are mostly Watch, not Access, because of their resistance impact, even though they are widely used and clinically important.

The target is about consumption, not the number of drugs. The 60%-then-70% figure refers to the share of total antibiotic use that is Access-group, a measure of prescribing behavior, not the proportion of drugs classified as Access.

AWaRe is a tool to apply, not just a list to memorize. Its value is in monitoring consumption, shaping formularies, guiding empirical therapy through the AWaRe antibiotic book, and protecting Reserve drugs. Knowing which group a drug is in is only the starting point.

References

1. World Health Organization. WHO AWaRe (Access, Watch, Reserve) Classification of Antibiotics for Evaluation and Monitoring of Use, 2023. Geneva: WHO; 2023. WHO/MHP/HPS/EML/2023.04.
2. World Health Organization. The WHO AWaRe Antibiotic Book. Geneva: WHO. (empirical guidance on antibiotic choice, dose, and duration for common infections)
3. World Health Organization. WHO Antibiotics Portal / AWaRe classification database. Available at: https://aware.essentialmeds.org
4. World Health Organization Model List of Essential Medicines. Geneva: WHO. (basis for the biennial AWaRe update cycle)